+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Phase 3
Age: 18Years +
All Genders
ID07005102

Evaluating Safety and Optimal Dosing of Telisotuzumab Adizutecan with Osimertinib Compared to Standard Care in Adults with Advanced EGFR-Mutated Non-Squamous NSCLC

Led by AbbVie · Updated on 2026-10-05

854

Participants Needed

65

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Non-small cell lung cancer NSCLC is a common lung cancer type where abnormal lung cells grow uncontrollably. This research evaluates the safety, optimal dose, and effect on disease activity of telisotuzumab adizutecan combined with osimertinib Osi compared to standard care in adults with locally advanced or metastatic EGFR-mutated non-squamous NSCLC. The study is conducted in two stages across about 76 months and includes approximately 854 participants worldwide. In the first stage, participants receive escalating intravenous doses of telisotuzumab adizutecan alongside oral osimertinib tablets or the standard care regimen of osimertinib plus chemotherapy. After dose escalation, participants are randomized into four treatment arms receiving different doses of telisotuzumab adizutecan with osimertinib or standard care. The second stage involves treatment with the optimal telisotuzumab adizutecan dose combined with osimertinib or standard care for the study duration. Participants attend regular visits at approved hospitals or clinics for medical assessments, blood tests, and questionnaires to monitor side effects and treatment effects. Researchers measure outcomes including tumor response, progression-free survival, and adverse events over the approximately 76-month study period. Quality of life and lung cancer symptom changes are also evaluated during treatment to assess overall impact.

CONDITIONS

Brief Title

A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

Research Team

A

ABBVIE CALL CENTER

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here